

**Literature Search**  
**ACR Appropriateness Criteria®**  
**Imaging of Ductal Carcinoma in Situ (DCIS)**

Literature Search Performed on: 06/13/2023

Beginning Date: January 2013

End Date: May 2023

Database: Ovid MEDLINE(R) ALL <1946 to June 12, 2023>

---

**Search Strategy**

- 1 Breast Neoplasms/ and (Carcinoma, Ductal, Breast/ or Carcinoma, Intraductal, Noninfiltrating/) (22859)
- 2 (breast biopsy or Trends of Breast Ductal Carcinoma In Situ or Mammography in Patients Diagnosed as Ductal Carcinoma In Situ or diagnosed with pure ductal carcinoma in situ or Good-Risk Ductal Carcinoma In Situ or clinically significant breast cancer in women or LORD study or Preoperative Letrozole or local therapy in patients with DCIS or COMET or LORIS or dedicated breast positron emission tomography or Active Surveillance Trials or ductal carcinoma in situ cases or Low-Risk Ductal Carcinoma In Situ or invasive recurrence among patients or Surveillance of Ductal Carcinoma in Situ or ductal carcinoma in situ versus invasive ductal carcinoma or supplementary ultrasound surveillance).tw. (17744)
- 3 1 and 2 (457)
- 4 ((dcis or ductal carcinoma in situ or breast cancer) and nccn clinical practice guidelines).tw. (41)
- 5 (preoperative evaluation of ductal carcinoma in situ or Contrast-Enhanced Mammographic Features of In Situ or Surveillance of Ductal Carcinoma In Situ or mammography in breast cancer surveillance).tw. (15)
- 6 3 or 4 or 5 (506)
- 7 limit 6 to yr="2013 -Current" (222)
- 8 limit 7 to case reports (12)
- 9 7 not 8 (210)
- 10 remove duplicates from 9 (209)

---

Literature Search Performed on: 06/09/2023

Beginning Date: January 2013

End Date: May 2023

Database: Ovid MEDLINE(R) ALL <1946 to June 08, 2023>

---

**Search Strategy**

- 1 Breast/dg, pa, su [Diagnostic Imaging, Pathology, Surgery] (23429)
- 2 Breast Neoplasms/ (329450)
- 3 Biopsy, Large-Core Needle/ (2440)
- 4 Carcinoma, Intraductal, Noninfiltrating/di, dg, ep, pa, su [Diagnosis, Diagnostic Imaging, Epidemiology, Pathology, Surgery] (8648)
- 5 Image-Guided Biopsy/mt, sn [Methods, Statistics & Numerical Data] (2739)
- 6 Magnetic Resonance Imaging/ (472543)
- 7 Neoplasm Invasiveness/ (90845)
- 8 Retrospective Studies/ (1122105)
- 9 Sentinel Lymph Node Biopsy/ (13219)
- 10 2 and 4 and 7 and ductal carcinoma in situ.tw. and (axillary or microinvasion).tw. (115)
- 11 (Axillary ultrasound for breast cancer staging or (ductal carcinoma in situ and ultrasound and core needle biopsy and breast)).tw. (68)
- 12 1 and 2 and 3 and (5 or hyperplasia/) and breast.tw. and (biopsy or biopsies).tw. (50)
- 13 2 and 4 and 6 and (biopsy or preoperative breast MR).tw. and (core or imaging features).tw. (50)
- 14 2 and 4 and 8 and (5 or 9) and (ductal carcinoma in situ or breast cancer).tw. (119)
- 15 10 or 11 or 12 or 13 or 14 (369)
- 16 Mammography/ (33119)
- 17 2 and 4 and Neoplasm Grading/ and DCIS.tw. and cancer.tw. and (locoregional or overdiagnosis).tw. (6)
- 18 4 and Carcinoma, Ductal, Breast/ and Genomics/ and ductal carcinoma in situ.tw. (7)
- 19 2 and 16 and Tomography/ and breast cancer.tw. (23)

**Literature Search**  
**ACR Appropriateness Criteria®**  
**Imaging of Ductal Carcinoma in Situ (DCIS)**

- 20 2 and 4 and 16 and Incidence/ and ductal carcinoma in situ.tw. (51)
- 21 2 and 8 and (Grimm or Friedewald).fa. (49)
- 22 (Tumor Recurrence and Ductal Carcinoma in Situ and Breast and DCIS).tw. or (16 and "BI-RADS 4".tw. and mammography.tw. and screened women.tw.) (95)
- 23 17 or 18 or 19 or 20 or 21 or 22 (231)
- 24 15 or 23 (595)
- 25 limit 24 to yr="2013 -Current" (372)
- 26 limit 25 to case reports (12)
- 27 25 not 26 (360)

---

Literature Search Performed on: 04/24/2023

Beginning Date: January 2013

End Date: March 2023

Database: Ovid MEDLINE(R) ALL <1946 to April 04, 2023>

---

**Search Strategy**

- 1 Breast/ (44559)
- 2 Breast Neoplasms/ (327495)
- 3 Carcinoma, Intraductal, Noninfiltrating/ (10585)
- 4 Carcinoma in Situ/ (16270)
- 5 Carcinoma, Ductal, Breast/ (16887)
- 6 Neoplasm Recurrence, Local/ (142363)
- 7 Lymphadenopathy/ (1745)
- 8 Neoplasm Invasiveness/ (90715)
- 9 Neoplasm Metastasis/ (113653)
- 10 Lymphatic Metastasis/ (96985)
- 11 Neoplasm Staging/ (191990)
- 12 Neoadjuvant Therapy/ (27855)
- 13 Mastectomy/ (25217)
- 14 Mastectomy, Segmental/ (10057)
- 15 Radiotherapy/ (44246)
- 16 Tamoxifen/ (20285)
- 17 Sentinel Lymph Node Biopsy/ (13123)
- 18 Biopsy, Needle/ (49740)
- 19 Lymphoscintigraphy/ (1148)
- 20 Physical Examination/ (43262)
- 21 Biomarkers, Tumor/ (176331)
- 22 Receptor, ErbB-2/ (28900)
- 23 ErbB Receptors/ (46830)
- 24 Overdiagnosis/ (151)
- 25 Overtreatment/ (153)
- 26 "Early Detection of Cancer"/ (36781)
- 27 Prognosis/ (590242)
- 28 Survival Analysis/ (145480)
- 29 Risk/ (128168)
- 30 "Sensitivity and Specificity"/ (368055)
- 31 Prospective Studies/ (655455)
- 32 Fluorodeoxyglucose F18/ (36037)

**Literature Search**  
**ACR Appropriateness Criteria®**  
**Imaging of Ductal Carcinoma in Situ (DCIS)**

- 33 exp Diagnostic Imaging/ (2899632)
- 34 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 (805359)
- 35 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 (456231)
- 36 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 (1789165)
- 37 ((nipple discharge or comedonecrosis or adenopathy or palpable or microinvasion or locoregional or local regional or nuclear grade or management or cancer detection rate or upgrade rate or underestimation or margin rate or carcinoma or screening) and breast).tw. (122883)
- 38 (DCIS or ductal carcinoma in situ).ti. (3438)
- 39 1 and 2 and Mammography/ and (DCIS or ductal carcinoma in situ).ti. (61)
- 40 5 and 13 and (DCIS or ductal carcinoma in situ).ti. (174)
- 41 2 and 3 and (8 or 9) and (DCIS or ductal carcinoma in situ).ti. and risk.ti. (38)
- 42 1 and 2 and 3 and Magnetic Resonance Imaging/ and (DCIS or ductal carcinoma in situ).ti. (21)
- 43 2 and 3 and 17 and sentinel lymph node biopsy.ti. and breast.ti. (64)
- 44 33 and 34 and 35 and 36 (7169)
- 45 33 and 37 and 38 (598)
- 46 39 or 40 or 41 or 42 or 43 (348)
- 47 44 or 45 or 46 (7901)
- 48 47 and (dcis or ductal carcinoma in situ).tw. (1017)
- 49 Practice Guideline/ and (dcis or ductal carcinoma in situ).tw. (28)
- 50 ((dcis or ductal carcinoma in situ) and (guideline\* or society or recommendation\* or consensus)).ti. (60)
- 51 (dcis or ductal carcinoma in situ).tw. (8996)
- 52 limit 51 to (guideline or practice guideline) (28)
- 53 "BI-RADS".ti. and (dcis or ductal carcinoma in situ).tw. (40)
- 54 2 and 26 and Mammography/ and Mass Screening/ and (DCIS or ductal carcinoma in situ).ab. (89)
- 55 47 or 48 or 49 or 50 or 52 or 53 or 54 (8078)
- 56 limit 55 to (abstracts and english language and humans and yr="2013 -Current") (3227)
- 57 limit 56 to "all child (0 to 18 years)" (145)
- 58 56 not 57 (3082)
- 59 limit 58 to case reports (100)
- 60 58 not 59 (2982)
- 61 2 and (3 or 5) and ((DCIS or ductal carcinoma in situ) and meta-analysis).ti. (25)
- 62 limit 61 to (abstracts and english language and humans and yr="2013 -Current") (18)
- 63 60 or 62 (2998)
- 64 remove duplicates from 63 (2997)

---

Literature Search Performed on: 04/24/2023

Beginning Date: January 2013

End Date: March 2023

Database: Ovid MEDLINE(R) ALL <1946 to April 04, 2023>

---

**Search Strategy**

- 1 Breast/ (44559)
- 2 Breast Neoplasms/ (327495)
- 3 Carcinoma, Intraductal, Noninfiltrating/ (10585)
- 4 Carcinoma in Situ/ (16270)
- 5 Carcinoma, Ductal, Breast/ (16887)
- 6 Neoplasm Recurrence, Local/ (142363)
- 7 Lymphadenopathy/ (1745)

**Literature Search**  
**ACR Appropriateness Criteria®**  
**Imaging of Ductal Carcinoma in Situ (DCIS)**

- 8 Neoplasm Invasiveness/ (90715)
- 9 Neoplasm Metastasis/ (113653)
- 10 Lymphatic Metastasis/ (96985)
- 11 Neoplasm Staging/ (191990)
- 12 Neoadjuvant Therapy/ (27855)
- 13 Mastectomy/ (25217)
- 14 Mastectomy, Segmental/ (10057)
- 15 Radiotherapy/ (44246)
- 16 Tamoxifen/ (20285)
- 17 Sentinel Lymph Node Biopsy/ (13123)
- 18 Biopsy, Needle/ (49740)
- 19 Lymphoscintigraphy/ (1148)
- 20 Physical Examination/ (43262)
- 21 Biomarkers, Tumor/ (176331)
- 22 Receptor, ErbB-2/ (28900)
- 23 ErbB Receptors/ (46830)
- 24 Overdiagnosis/ (151)
- 25 Overtreatment/ (153)
- 26 "Early Detection of Cancer"/ (36781)
- 27 Prognosis/ (590242)
- 28 Survival Analysis/ (145480)
- 29 Risk/ (128168)
- 30 "Sensitivity and Specificity"/ (368055)
- 31 Prospective Studies/ (655455)
- 32 Fluorodeoxyglucose F18/ (36037)
- 33 exp Diagnostic Imaging/ (2899632)
- 34 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 (805359)
- 35 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 (456231)
- 36 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 (1789165)
- 37 ((nipple discharge or comedonecrosis or adenopathy or palpable or microinvasion or locoregional or local regional or nuclear grade or management or cancer detection rate or upgrade rate or underestimation or margin rate or carcinoma or screening) and breast).tw. (122883)
- 38 (DCIS or ductal carcinoma in situ).ti. (3438)
- 39 1 and 2 and Mammography/ and (DCIS or ductal carcinoma in situ).ti. (61)
- 40 5 and 13 and (DCIS or ductal carcinoma in situ).ti. (174)
- 41 2 and 3 and (8 or 9) and (DCIS or ductal carcinoma in situ).ti. and risk.ti. (38)
- 42 1 and 2 and 3 and Magnetic Resonance Imaging/ and (DCIS or ductal carcinoma in situ).ti. (21)
- 43 2 and 3 and 17 and sentinel lymph node biopsy.ti. and breast.ti. (64)
- 44 33 and 34 and 35 and 36 (7169)
- 45 33 and 37 and 38 (598)
- 46 39 or 40 or 41 or 42 or 43 (348)
- 47 44 or 45 or 46 (7901)
- 48 47 and (dcis or ductal carcinoma in situ).tw. (1017)
- 49 Practice Guideline/ and (dcis or ductal carcinoma in situ).tw. (28)
- 50 ((dcis or ductal carcinoma in situ) and (guideline\* or society or recommendation\* or consensus)).ti. (60)
- 51 (dcis or ductal carcinoma in situ).tw. (8996)
- 52 limit 51 to (guideline or practice guideline) (28)
- 53 "BI-RADS".ti. and (dcis or ductal carcinoma in situ).tw. (40)
- 54 2 and 26 and Mammography/ and Mass Screening/ and (DCIS or ductal carcinoma in situ).ab. (89)
- 55 47 or 48 or 49 or 50 or 52 or 53 or 54 (8078)

**Literature Search**  
**ACR Appropriateness Criteria®**  
**Imaging of Ductal Carcinoma in Situ (DCIS)**

- 56 limit 55 to (abstracts and english language and humans and yr="2013 -Current") (3227)
- 57 limit 56 to "all child (0 to 18 years)" (145)
- 58 56 not 57 (3082)
- 59 limit 58 to case reports (100)
- 60 58 not 59 (2982)
- 61 2 and (3 or 5) and ((DCIS or ductal carcinoma in situ) and meta-analysis).ti. (25)
- 62 limit 61 to (abstracts and english language and humans and yr="2013 -Current") (18)
- 63 60 or 62 (2998)
- 64 remove duplicates from 63 (2997)

---

Literature Search Performed on: 04/24/2023

Beginning Date: January 2013

End Date: March 2023

Database: Ovid MEDLINE(R) ALL <1946 to April 04, 2023>

---

**Search Strategy**

- 1 Breast/ (44559)
- 2 Breast Neoplasms/ (327495)
- 3 Carcinoma, Intraductal, Noninfiltrating/ (10585)
- 4 Carcinoma in Situ/ (16270)
- 5 Carcinoma, Ductal, Breast/ (16887)
- 6 Neoplasm Recurrence, Local/ (142363)
- 7 Lymphadenopathy/ (1745)
- 8 Neoplasm Invasiveness/ (90715)
- 9 Neoplasm Metastasis/ (113653)
- 10 Lymphatic Metastasis/ (96985)
- 11 Neoplasm Staging/ (191990)
- 12 Neoadjuvant Therapy/ (27855)
- 13 Mastectomy/ (25217)
- 14 Mastectomy, Segmental/ (10057)
- 15 Radiotherapy/ (44246)
- 16 Tamoxifen/ (20285)
- 17 Sentinel Lymph Node Biopsy/ (13123)
- 18 Biopsy, Needle/ (49740)
- 19 Lymphoscintigraphy/ (1148)
- 20 Physical Examination/ (43262)
- 21 Biomarkers, Tumor/ (176331)
- 22 Receptor, ErbB-2/ (28900)
- 23 ErbB Receptors/ (46830)
- 24 Overdiagnosis/ (151)
- 25 Overtreatment/ (153)
- 26 "Early Detection of Cancer"/ (36781)
- 27 Prognosis/ (590242)
- 28 Survival Analysis/ (145480)
- 29 Risk/ (128168)
- 30 "Sensitivity and Specificity"/ (368055)
- 31 Prospective Studies/ (655455)
- 32 Fluorodeoxyglucose F18/ (36037)

**Literature Search**  
**ACR Appropriateness Criteria®**  
**Imaging of Ductal Carcinoma in Situ (DCIS)**

- 33 exp Diagnostic Imaging/ (2899632)  
34 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 (805359)  
35 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 (456231)  
36 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 (1789165)  
37 ((nipple discharge or comedonecrosis or adenopathy or palpable or microinvasion or locoregional or local regional or nuclear grade or management or cancer detection rate or upgrade rate or underestimation or margin rate or carcinoma or screening) and breast).tw. (122883)  
38 (DCIS or ductal carcinoma in situ).ti. (3438)  
39 1 and 2 and Mammography/ and (DCIS or ductal carcinoma in situ).ti. (61)  
40 5 and 13 and (DCIS or ductal carcinoma in situ).ti. (174)  
41 2 and 3 and (8 or 9) and (DCIS or ductal carcinoma in situ).ti. and risk.ti. (38)  
42 1 and 2 and 3 and Magnetic Resonance Imaging/ and (DCIS or ductal carcinoma in situ).ti. (21)  
43 2 and 3 and 17 and sentinel lymph node biopsy.ti. and breast.ti. (64)  
44 33 and 34 and 35 and 36 (7169)  
45 33 and 37 and 38 (598)  
46 39 or 40 or 41 or 42 or 43 (348)  
47 44 or 45 or 46 (7901)  
48 47 and (dcis or ductal carcinoma in situ).tw. (1017)  
49 Practice Guideline/ and (dcis or ductal carcinoma in situ).tw. (28)  
50 ((dcis or ductal carcinoma in situ) and (guideline\* or society or recommendation\* or consensus)).ti. (60)  
51 (dcis or ductal carcinoma in situ).tw. (8996)  
52 limit 51 to (guideline or practice guideline) (28)  
53 "BI-RADS".ti. and (dcis or ductal carcinoma in situ).tw. (40)  
54 2 and 26 and Mammography/ and Mass Screening/ and (DCIS or ductal carcinoma in situ).ab. (89)  
55 47 or 48 or 49 or 50 or 52 or 53 or 54 (8078)  
56 limit 55 to (abstracts and english language and humans and yr="2013 -Current") (3227)  
57 limit 56 to "all child (0 to 18 years)" (145)  
58 56 not 57 (3082)  
59 limit 58 to case reports (100)  
60 58 not 59 (2982)  
61 2 and (3 or 5) and ((DCIS or ductal carcinoma in situ) and meta-analysis).ti. (25)  
62 limit 61 to (abstracts and english language and humans and yr="2013 -Current") (18)  
63 60 or 62 (2998)  
64 remove duplicates from 63 (2997)

**Summary**

Source	#Unique Refs	#Retained Refs
Old bibliography	0	0
Literature Search(es)	3413	22
Author Added	126	89
Supporting Docs	8	8
Total		119

References from the literature search that were not retained had a poor study design, were not relevant to the topic, or had unclear or biased results.